Introduction {#Sec1}
============

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults and the 5-year survival rate is \<5% in adults \[[@CR1], [@CR2]\]. According to the guidelines of the National Guideline Clearinghouse of the U.S. Department of Health & Human Services, the recommended therapy for a newly diagnosed GBM is surgical debulking provided that unacceptable neurologic deficit can be avoided, followed by adjuvant radiotherapy \[[@CR3], [@CR4]\]. Concomitant radiotherapy and temozolomide followed by adjuvant temozolomide for 6 courses have been shown to significantly prolong overall survival (OS) compared to radiotherapy alone \[[@CR5], [@CR6]\]. The median OS in patients treated with additional temozolomide is prolonged from 12.1 months to 14.6 months when compared to radiotherapy alone. In addition, the 2-year survival is improved from 10.4% with radiotherapy alone to 26.5% with radiotherapy and temozolomide \[[@CR6]\]. Due to their invasive growth pattern, GBM have a high relapse rate \[[@CR7]\]. According to the guidelines of the National Comprehensive Cancer Network (NCCN), the recommended therapy for a resectable locally relapsed GBM is resection with or without implantation of a carmustine wafer. However, there is no clearly defined standard therapy for relapsed unresectable GBM \[[@CR8], [@CR9]\]. In this case, the treatment decision depends on multiple parameters such as prior therapy, time to relapse, tumor grade, and performance status \[[@CR8], [@CR9]\]. Treatment options include repeated surgery, radiation, or chemotherapy \[[@CR10]\]. Chemotherapeutic regimes include either monotherapy with lomustine (CCNU), platinum compounds, or temozolomide \[[@CR9], [@CR11], [@CR12]\]. Alternatively, medically fit and healthy patients can be treated with polychemotherapy using regimens such as procarbacin/CCNU/vincristin (PCV) \[[@CR13]\]. Two uncontrolled phase II studies showed that the monoclonal human anti-VEGF-antibody bevacizumab, alone or in combination with irinotecan, prolongs progression-free survival (PFS) and overall survival (OS) in patients with relapsed GBM compared to historical data \[[@CR14], [@CR15]\]. Based on this data, bevacizumab was approved by the US Food and Drug administration (FDA) for use in relapsed GBM. However, it is currently not approved by the European Medicines Agency (EMA) for relapsed GBM because of missing evidence that bevacizumab prolongs survival. In 2013, Johnson *et al*. published a population-based analysis in which they compared patients in the United States who eventually succumbed to GBM in 2006, 2008, and 2010 \[[@CR16]\]. The difference in survival between 2008 and 2010 was significantly better for patients treated with bevacizumab \[[@CR16]\]. This circumstantial evidence suggests that the improved median survival of GBM patients in the US might be due to the approval and use of bevacizumab, however a direct comparison of subpopulations is missing so far. Here we report on the successful long-term treatment of a relapsed GBM patient with bevacizumab as monotherapy for the last 26 months with an ongoing improvement in tumor volume and quality of life.

Case report {#Sec2}
===========

In November 2011, a 53-year-old male patient presented to our clinics for chemoradiotherapy after resection of a cerebral lesion that was diagnosed as GBM WHO IV° by histopathology. An epigenetic silencing of O^6^-methylguanine-DNA methyltransferase (MGMT) by promoter methylation was not detected by real-time PCR of tumor DNA. Approximately six weeks after resection, the patient was started on standard combined chemotherapy and radiation (temozolomide 75 mg/m^2^/day and involved-field radiation at a total dose of 60 Gy in 2.0 Gy fractions over a 6-week period). The radiotherapy was well tolerated and the treatment with temozolomide was continued with 150 mg/m^2^ d1-5 in the first cycle followed by 200 mg/m^2^ d1-5 every 4 weeks. In April 2012, after three courses of temozolomide, the patient presented with intermittent disorientation and a worsened general condition. The native and Gadolinium-enhanced T1-weighted cerebral magnetic resonance imaging (cMRI) showed a tumor involving the right basal ganglia with strong peripheral and irregular contrast enhancement (Figure [1](#Fig1){ref-type="fig"}A and B). In the T2-weighted FLAIR a pronounced surrounding edema and mass effect was seen in the area of the basal ganglia (Figure [1](#Fig1){ref-type="fig"}C). Because of the clinical symptoms, the deteriorated general condition, and the unmethylated MGMT promoter status \[[@CR17]\] these radiographic findings were interpreted as GBM relapse. A radiotherapy-induced pseudoprogression is not considered to cause the radiographic findings. To confirm this we performed ^18^ F-fluoroethyltyrosine-positron emission tomography/computer tomography (FET-PET/CT) scan (Figure [1](#Fig1){ref-type="fig"}D and E). The PET/CT (Figure [1](#Fig1){ref-type="fig"}D) showed a focally increased ^18^ F-FET uptake corresponding to the contrast enhancement described in cMRI, which was emphasized in the fusion of PET and MRI (Figure [1](#Fig1){ref-type="fig"}E). The mean tumoral uptake (Tu) was evaluated and the ratio to background (Bg) was calculated with Tu/Bg ratio of 2.4. This value exceeds the threshold of 1.6 thereby indicating an active malignancy \[[@CR18]\]. Because of the localization of the relapsed GBM and the reduced general performance status, resection was deemed impossible. It was decided to treat the patient with anti-VEGF antibody (bevacizumab) monotherapy (Avastin®) in an off-label setting. Bevacizumab was given at a dose of 10 mg/kg body weight on d1 and d15 every four weeks. Concurrently, the palliative care team was involved in patient's care because of the poor general performance status. After three courses, a reduction in tumor size from 51 × 21 × 25 mm to 39 × 17 × 17 mm was observed at Gadolinium-enhanced T1-weighted cMRI, and the degree of contrast enhancement within the tumor had decreased (Figure [2](#Fig2){ref-type="fig"}). On day one of the forth course of bevacizumab, our patient presented with dyspnoe at the emergency room and the suspected diagnosis of pulmonary embolism was confirmed by CT scan. Therapeutic anticoagulation was started using low molecular weight heparin. Bevacizumab was continued one week later at the initially used dosing regimen. Under low molecular weight heparin, there were no further thromboembolic events or other bevacizumab-related serious adverse reactions until to date. During ongoing therapy with bevacizumab, the patient's Karnofsky performance status improved steadily from 50% at the beginning of treatment with bevacizumab to 80% after 6 months and the palliative care team stopped patient's care. Concomitant corticosteroid therapy was reduced continuously and finally stopped. The last cMRI performed after 17 courses of bevacizumab showed a very good partial response to bevacizumab therapy with a tumor size of 35 × 15 × 15 mm in the unenhanced T1-weighted sequences (Figure [3](#Fig3){ref-type="fig"}A) and a lack of contrast enhancement in the lateral portions of the tumor in the Gadolinium-enhanced T1-weighted sequences (Figure [3](#Fig3){ref-type="fig"}B). T2-weighted FLAIR demonstrated a significant decrease of peritumoral edema (Figure [3](#Fig3){ref-type="fig"}C). A very low level of ^18^ F-FET tracer uptake was noted (Figure [4](#Fig4){ref-type="fig"}), which was substantially lower than the tracer uptake observed before treatment (Figure [1](#Fig1){ref-type="fig"}D and E). Moreover, Tu/Bg ratio in the post treatment PET/CT scan was 1.3 consistent with reactive changes after treatment (Figure [4](#Fig4){ref-type="fig"}). After the excellent treatment response observed under bevacizumab treatment, we evaluated to stop monotherapy with bevacizumab. However, since remaining active tumor cannot be fully excluded by the imaging modalities used, we decided together with the interdisciplinary tumor board to further extend the treatment.Figure 1**Relapse of GBM after resection and radiochemotherapy. A** Native T1-weighted MRI shows a tumor involving the right basal ganglia. **B** Gadolinium-enhanced T1-weighted MRI shows strong peripheral and irregular enhancement of the tumor. **C** T2-weighted FLAIR demonstrates pronounced surrounding edema and mass effect. **D** In the PET/CT scan and **E** the fusion of PET and MRI, the lesion described in the MRI corresponds with focal increased ^18^ F-FET uptake exhibiting Tu/Bg ratio of 2.4.Figure 2**GBM after three courses of bevacizumab.** Gadolinium-enhanced T1-weighted MRI shows a reduction in tumor size as well as decreasing and discontinuous tumor enhancement.Figure 3**Treatment response after 17 courses of bevacizumab in cMRI. A** Non-enhanced T1-weighted MRI reveals further decrease in lesion size. Hyperintense hemorrhagic changes are present within the medial portion of the tumor. **B** Gadolinium-enhanced T1-weighted MRI documents lack of contrast enhancement in the lateral portions of the tumor. Only a slight enhancement in addition to the hyperintense hemorrhagic changes in the medial portion of the tumor was observed. **C** T2-weighted FLAIR demonstrates a decrease of peritumoral edema.Figure 4**Treatment response after 17 courses of bevacizumab in** ^**18**^ **F-FET-PET/CT and fusion of PET with MRI. A** The native and **B** the contrast-enhanced T1 cMRT scans show a decrease of the lesion initially described. **C** In the PET/CT and **D** the fusion of PET and MRI, the ^18^ F-FET uptake is slightly diffuse increased with Tu/Bg uptake ration of 1.3 consitent with reactive changes after treatment and arguing against vital tumor tissue.

26 months after the diagnosis of relapsed GBM, our patient remains in an excellent general condition with a Karnofsky performance status of 100% without further adverse side effects to the current therapy. Under ongoing treatment with bevacizumab the patient is able to live a self-reliant, socially active life.

Discussion {#Sec3}
==========

Despite therapeutic advances, the prognosis for patients with GBM is still poor \[[@CR19]\]. Nevertheless, a small fraction of patients with GBM (3--5%) survive longer that 36 months and they are referred to as long-term survivors \[[@CR2]\]. Young age, female gender, higher preoperative Karnofsky performance status, unilateral tumor, gross total resection, and adjuvant radiochemotherapy are associated with prolonged survival \[[@CR20]\]. Furthermore, there are some molecular markers, e.g. p53 mutation, MGMT promoter methylation, or isocitrate dehydrogenase 1 (IDH1) mutations that are frequently found in long-term survivors \[[@CR20]\]. Single amino acid mutations in IDH1 can lead to the loss of regular enzyme function \[[@CR21]\]. The mutated IDH1 converts α-ketoglutarate to the oncometabolite 2-hydroxyglutarate (2-HG), which causes genome-wide epigenetic changes in human gliomas \[[@CR22]\]. Patients harboring mutated IDH1 and corresponding epigenetic changes have a better prognosis than patients diagnosed with GBM with wild-type IDH1 \[[@CR21], [@CR23]\]. This is exemplified by the fact that treatment with bevacizumab as single agent in patients with relapsed GBM and IDH1 mutation results in a significant better PFS and OS compared to patients without IDH1 mutation (PFS 3.23 *vs.* 1.37 months, *p* = 0.05; and OS 10.16 *vs.* 4.90 months, *p* = 0.09) \[[@CR24]\].

The MGMT promoter methylation is known to play an important role in the cellular response to alkylating agents such as temozolomide \[[@CR5], [@CR25]\]. Significantly more long-term survivors harbor MGMT promoter methylation compared to patients that survive shorter than 18 months \[[@CR20]\]. Furthermore, Capdevila and colleagues showed, that patients with methylated MGMT promoter status derive greater benefit from neoadjuvant temozolomide treatment than those without methylated MGMT promoter status \[[@CR26]\]. Concerning bevacizumab, a previously published single-arm study showed that patients with a relapsed GBM treated with the combination of bevacizumab and fotemustin had an improved PFS when the MGMT promoter was methylated \[[@CR27]\], however the difference to historical controls was not statistically significant. An alternative single-arm study used bevacizumab in combination with temozolomide after radiotherapy in newly diagnosed GBM patients \[[@CR28]\]. In this study, patients with MGMT promoter methylation had an improved median OS and PFS compared to patients without MGMT promoter methylation \[[@CR28]\]. The patients of the MGMT unmethylated group appeared to have a poor outcome, possibly caused by the reduced effectiveness of temozolomide.

Since the approval of bevacizumab for relapsed GBM by the FDA, there is an ongoing attempt to improve the anti-tumor effect of bevacizumab using combination therapies. Several studies have analyzed the combination of bevacizumab with various chemotherapeutic agents that are recommended as second-line therapy for relapsed unresectable GBM. In these studies, bevacizumab was combined with irinotecan \[[@CR14], [@CR29], [@CR30]\], oral etoposide \[[@CR31]\], temozolomide \[[@CR32]\], carboplatin and etoposide \[[@CR33]\], or carboplatin and irinotecan \[[@CR34]\]. All these combination therapies were effective treatments for relapsed GBM, but did not improve the outcome over the level observed with bevacizumab alone.

The presented case shows that monotherapy with bevacizumab can substantially prolong survival and improve quality of life in patients with relapsed GBM. This argues that a better understanding of the clinical or molecular parameters that define the patient population that will profit from bevacizumab monotherapy is urgently needed. At this point, it is not clear whether a definite correlation exists between improved PFS and OS in patients treated with bevacizumab as monotherapy and their MGMT methylation status. The patient's current survival time of 26 months from start of monotherapy with bevacizumab after relapsed GBM exceeds all expectations and surpasses to our knowledge survival rates of other studies or reports. The patient remains in an excellent general condition under ongoing treatment with bevacizumab. At this point, we have no explanation for this successful course, particularly taking into consideration the reduced Karnofsky performance status of 50% at time of relapse, male gender and unmethylated MGMT promoter as negative prognostic survival markers. Therefore, additional clinical trials and an improved molecular characterization of these cases might help to identify patient populations that will likely benefit from an anti-VEGF therapy.
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